Kyron.bio uses precision engineering of glycosylation to deliver better therapies for patients.

Two thirds of the $562B dollar a year biologics on the market have carbohydrate moieties known as glycans added to them which are vitally important for function and stability of the drug. However the type and number of these glycan added is poorly controlled, leading to suboptimal performance of the drug, poor stability and aggregation issues. Kyron.bio’s proprietary technology controls the addition of these glycans, driving the development of improved therapies for patients.